Systemic Sclerosis (Scleroderma) - Epidemiology Forecast to 2030

Systemic Sclerosis (Scleroderma) - Epidemiology Forecast to 2030

Summary

Systemic sclerosis (SSc) is an autoimmune disorder of small arteries, microvessels, and connective tissue. SSc is characterized by the buildup of scar tissue (fibrosis) and vascular obliteration in the skin and organs, particularly the lungs, heart, and digestive tract (Orphanet, 2010). The signs and symptoms of SSc usually begin with episodes of Raynauds phenomenon (RP). The other signs usually appear a few months later in the dcSSc subset and some years later in the lcSSc subset. In lcSSc, skin involvement is limited to the hands, face, feet and forearms while in the dcSSc it rapidly becomes generalized. The most commonly affected organs are the esophagus, heart, lungs, and kidneys (Genetic and Rare Diseases Information Center, 2018).

This report provides an overview of the risk factors, comorbidities, and the global and historical epidemiological trends for SSc in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan). The report includes a 10-year epidemiology forecast for the diagnosed prevalent cases of SSc. The diagnosed prevalent cases of SSc are segmented by age (18 years and older), sex, subtype (lcSSc and dcSSc), digital vasculopathy (RP and fingertip or DUs), and other internal organ involvement (ILD, PAH, kidney disease, cardiac involvement, gastrointestinal involvement, musculoskeletal involvement, and neuromuscular involvement). The report also includes SSc cases with comorbid malignancy. The following data describes epidemiology of SSc. In the 7MM, GlobalData epidemiologists forecast an increase in the diagnosed prevalent cases of SSc from 170,921 cases in 2020 to 187,518 cases in 2030, at an AGR of 0.97% over the forecast period. Women accounted for more diagnosed prevalent cases of SSc than men in the 7MM and it predominantly affects older adults. These findings are in line with the GlobalData estimates and these trends are reflected in GlobalDatas forecast for the diagnosed prevalent cases for the 7MM.

Scope

- The Systemic Sclerosis (SSc) Epidemiology Report provides an overview of the risk factors and global trends of SSc in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan).
- The report includes a 10-year epidemiological forecast for the diagnosed prevalent cases of SSc segmented by sex and age (ages 18 years). The diagnosed prevalent cases of SSc are further segmented by subtype (lcSSc and dcSSc), digital vasculopathy (Raynauds phenomenon [RP] and fingertip or digital ulcers [DU]), and other internal organ involvement (interstitial lung disease [ILD], pulmonary arterial hypertension [PAH], kidney disease, cardiac involvement, gastrointestinal involvement, musculoskeletal involvement, and neuromuscular involvement). The report also includes SSc cases with comorbid malignancy. The model associated with this report additionally provides diagnosed incident cases and total prevalent cases of SSc segmented by age (18 years) and sex.
- The SSc epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
- The Epidemiology Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.

Reasons to Buy

The Systemic Sclerosis Epidemiology series will allow you to -
- Develop business strategies by understanding the trends shaping and driving the global SSc market.
- Quantify patient populations in the global SSc market to improve product design, pricing, and launch plans.
- Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for SSc therapeutics in each of the markets covered.
- Understand magnitude of SSc population by subtype, digital vasculopathy, and other internal organ involvement.

Table of Contents
1 Systemic Sclerosis: Executive Summary
1.1 Catalyst
1.2 Related Reports
1.3 Upcoming Reports
2 Epidemiology
2.1 Disease Background
2.2 Risk Factors and Comorbidities
2.3 Global and Historical Trends
2.4 7MM Forecast Methodology
2.4.1 Sources
2.4.2 Forecast Assumptions and Methods
2.4.3 Forecast Assumptions and Methods: Diagnosed Prevalent Cases of SSc - 7MM
2.4.4 Forecast Assumptions and Methods: Diagnosed Prevalent Cases of SSc by Subtype
2.4.5 Diagnosed Prevalent Cases of SSc by Digital Vasculopathy
2.4.6 Diagnosed Prevalent Cases of by other Internal Organ Involvement and Comorbidities
2.5 Epidemiological Forecast for Systemic Sclerosis (Scleroderma) (2020-2030)
2.5.1 Diagnosed Prevalent Cases of SSc
2.5.2 Age-Specific Diagnosed Prevalent Cases of SSc
2.5.3 Sex-Specific Diagnosed Prevalent Cases of SSc
2.5.4 Diagnosed Prevalent Cases of SSc by Subtype
2.5.5 Diagnosed Prevalent Cases of SSc by Digital Vasculopathy
2.5.6 Diagnosed Prevalent Cases of SSc by Other Internal Organ Involvement
2.5.7 Diagnosed Prevalent Cases of SSc with Comorbid Malignancy
2.6 Discussion
2.6.1 Epidemiological Forecast Insight
2.6.2 COVID-19 Impact
2.6.3 Limitations of the Analysis
2.6.4 Strengths of the Analysis
3 Appendix
3.1 Bibliography
3.2 About the Authors
3.2.1 Epidemiologist
3.2.2 Reviewers
3.2.3 Global Director of Therapy Analysis and Epidemiology
3.2.4 Global Head and EVP of Healthcare Operations and Strategy
3.3 Contact Us

List Of Tables

List of Tables
Table 1: Summary of Newly Added Data Types
Table 2: Summary of Updated Data Types
Table 3: Risk Factors and Comorbidities for SSc
Table 4: Diagnosed Prevalent Cases of SSc by Other Internal Organ Involvement

List Of Figures

List of Figures
Figure 1: 7MM, Diagnosed Prevalent Cases of SSc, Both Sexes, N, Ages 18 Years, 2020 and 2030
Figure 2: 7MM, Diagnosed Prevalence of SSc, Men and Women, %, Ages 18 Years, 2020
Figure 3: 7MM, Sources Used and Not Used to Forecast the Diagnosed Prevalent Cases of SSc
Figure 4: 7MM, Sources Used to Forecast the Diagnosed Prevalent Cases of SSc by Subtype
Figure 5: 7MM, Sources Used to Forecast the Diagnosed Prevalent Cases of SSc by Digital Vasculopathy
Figure 6: 7MM, Sources Used to Forecast the Diagnosed Prevalent Cases of SSc by Other Internal Organ Involvement - ILD, PAH, and Kidney Disease
Figure 7: 7MM, Sources Used to Forecast the Diagnosed Prevalent Cases of SSc by Other Internal Organ Involvement - Cardiac Involvement, Gastrointestinal Involvement, Musculoskeletal Involvement, and Neuromuscular Involvement; and Comorbidity - Malignancy
Figure 8: 7MM, Diagnosed Prevalent Cases of SSc, N, Both Sexes, Ages 18 Years, 2020
Figure 9: 7MM, Diagnosed Prevalent Cases of SSc by Age, N, Both Sexes, 2020
Figure 10: 7MM, Diagnosed Prevalent Cases of SSc by Sex, N, Ages 18 Years, 2020
Figure 11: 7MM, Diagnosed Prevalent Cases of SSc by Subtype, N, Both Sexes, Ages 18 Years, 2020
Figure 12: 7MM, Diagnosed Prevalent Cases of SSc by Digital Vasculopathy, N, Both Sexes, Ages 18 Years, 2020
Figure 13: 7MM, Diagnosed Prevalent Cases of SSc with Comorbid Malignancy, N, Both Sexes, Ages 18 Years, 2020

Fill The Form For Sample Request

Full Name*

Business Email *

E-mail

Country *

Select Country Albania Algeria Afghanistan Angola Argentina Armenia Aruba Australia Austria Azerbaijan Andorra Anguilla Bahrain Bangladesh Barbados Belarus Belgium Benin Bermuda Bhutan Bolivia Bosnia and Herzegovina Botswana Brazil Brunei Bulgaria Burkina Faso Burundi Bosnia Cambodia Cameroon Central African Republic Chad Chile China Colombia Comoros Congo (Brazzaville) Cook Islands Costa Rica Cote d Ivoire Croatia Cuba Cyprus Czech Republic Cayman Islands Denmark Djibouti Dominican Republic Ecuador Egypt El Salvador Equatorial Guinea Eritrea Estonia Ethiopia Fiji Finland France Gabon Gambia Georgia Germany Ghana Gibraltar Greece Guam Guatemala Guernsey Guinea Guinea-Bissau Guyana Haiti Honduras Hong Kong Hungary Herzegovina Iceland India Indonesia Iran Iraq Ireland Isle of Man Israel Italy Jamaica Japan Jersey Jordan Kazakhstan Kenya Kiribati Kuwait Korea Kyrgyzstan Laos Latvia Lebanon Lesotho Liberia Libya Lithuania Luxembourg Liechtenstein Macau Macedonia Madagascar Malawi Malaysia Maldives Mali Malta Marshall Islands Mauritania Mauritius Mexico Moldova Monaco Mongolia Montenegro Morocco Mozambique Myanmar Middle East & North Africa (MENA) Namibia Nauru Nepal Netherlands New Caledonia New Zealand Nicaragua Niger Nigeria North Korea Norway Oman Pakistan Palau Palestinian Territories Panama Papua New Guinea Paraguay Peru Philippines Poland Portugal Puerto Rico Palestine Qatar Romania Russia Rwanda Samoa Saudi Arabia Senegal Serbia Seychelles Sierra Leone Singapore Slovakia Slovenia Solomon Islands Somalia South Africa South Korea Spain Sri Lanka Saint Kitts and Nevis Saint Vincent and the Grenadines Sudan Suriname Swaziland Sweden Switzerland Syria Scotland San Marino Taiwan Tajikistan Tanzania Thailand Timor-Leste Togo Tonga Trinidad and Tobago Tunisia Turkey Turkmenistan Turks and Caicos Islands Tuvalu Uganda Ukraine United Arab Emirates United Kingdom United States of America Uruguay Uzbekistan Uraguay Vanuatu Venezuela Vietnam Virgin Islands Yemen Zambia Zimbabwe Canada Grenada Cape Verde Belize Curacao Republic of Srpska Antigua and Barbuda Saint Lucia Falkland Islands Faroe Islands Federated States of Micronesia Guadeloupe Martinique Montserrat Niue

Contact No *

Alternate No

Note : * Kindly provide us with your company id and get the sample reports at the earliest.

There is no Reviews available